SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Akums Drugs & Pharma lists with 7% premium on the BSE

06 Aug 2024 Evaluate

Akums Drugs & Pharma has debuted at Rs 725.00 on the BSE, up by 46 points or 6.77% from its issue price of Rs 679.00. 

The scrip is currently trading at Rs 762.65, up by 83.65 points or 12.32% from its issue price. 

It has touched a high and low of Rs 784.65 and Rs 724.50 respectively. So far 5.96 lakh shares were traded on the counter.

The offering, which was open for subscription between July 30, 2024 and August 01, 2024 was subscribed 63.56 times. The issue price was fixed at Rs 679.00 per share i.e. at upper end of price band of Rs 646-679 apiece. 

Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.

Akums Drugs & Pharma Share Price

534.10 0.75 (0.14%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×